Delving into the Latest Updates on Pembrolizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Lambrolizumab, Pembrolizumab (Genetical Recombination), Pembrolizumab (genetical recombination) (JAN)

+ [12]

Target

PD-1

Action

inhibitors

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [13]

Active Indication

Carcinoma of urinary bladder, invasivePlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+ [323]

Inactive Indication

Acral Lentiginous Malignant MelanomaAcute Myeloid LeukemiaAcute myeloid leukemia with mutated NPM1+ [122]

Originator Organization

Merck & Co., Inc.

Active Organization

Merck Sharp & Dohme BV

MSD R&D (China) Co. Ltd.

Merck Sharp & Dohme Corp.

+ [16]

Inactive Organization

Turnstone Biologics Corp.Merck Sharp & Dohme (Ireland) Ltd.

Viralytics Pty Ltd.

License Organization

Nektar Therapeutics

NeoImmuneTech, Inc.

Canada Pension Plan Investment Board

+ [80]

Drug Highest PhaseApproved

First Approval Date

United States (04 Sep 2014),

Melanoma

RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), PRIME (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), Conditional marketing approval (China)

Login to view timeline

Structure/Sequence

Sequence Code 93660H

Source: *****

Sequence Code 93670L

Source: *****

This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with advanced squamous non-small cell lung cancer (NSCLC) or squamous cell carcinoma of head and neck (SCCHN).

Start Date20 May 2027

Sponsor / Collaborator

Lineberger Comprehensive Cancer Center

NCT07689240

/ Not yet recruitingPhase 3IIT

Phase III Study of Adjuvant Pembrolizumab vs Active Surveillance After Nephrectomy in Patients With Non-Clear Cell Renal-Cell Carcinoma

This phase III trial compares the effect of pembrolizumab to active surveillance after a surgical procedure to completely or partially remove a kidney (nephrectomy) in improving time without disease in patients with non-clear cell renal cell cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after nephrectomy may be more effective than the usual active surveillance approach for improving time without disease in patients with non-clear cell renal cell cancer.

Start Date10 Feb 2027

Sponsor / Collaborator

National Cancer Institute

ACTRN12626000937314

/ Not yet recruitingPhase 2IIT

IMPACT - A phase 2 study of IMmunotherapy with Pembrolizumab and sACituzumab Tirumotecan in pMMR recurrent or advanced endometrial cancer

Start Date01 Feb 2027

Sponsor / Collaborator-

100 Clinical Results associated with Pembrolizumab

Login to view more data

100 Translational Medicine associated with Pembrolizumab

Login to view more data

100 Patents (Medical) associated with Pembrolizumab

Login to view more data

11,523

Literatures (Medical) associated with Pembrolizumab

31 Dec 2026·Human Vaccines & Immunotherapeutics

Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report

Article

Author: Zhuang, Yihan ; Chen, Qiongshan ; Lin, Wen ; Chen, Zipei

Anaplastic thyroid cancer is a notoriously aggressive malignancy with a dismal prognosis, typically associated with a median overall survival of less than one year. Therapeutic alternatives are particularly limited for patients without actionable driver mutations. Here, we report a case of BRAF V600E wild-type, PD-L1-positive (tumor proportion score of 80%) anaplastic thyroid cancer with residual/relapsed disease following surgery and subsequent progression on multi-targeted tyrosine kinase inhibitor therapy. The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.

31 Dec 2026·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study

Article

Author: Wang, Ting ; Chen, Jinyun ; Ouyang, Bing ; Chen, Li ; Chen, Wenzhi

BACKGROUND:

This single-arm, open-label clinical trial aimed to evaluate the preliminary safety, efficacy and feasibility of focused ultrasound ablation surgery (FUAS) sequential with immune checkpoint inhibitors (ICIs) in patients with driver-gene wild-type non-small cell lung cancer (NSCLC) and liver metastases.

MATERIALS AND METHODS:

Ten eligible patients received two cycles of FUAS sequential with ICIs. The ICIs used include Camrelizumab (7/10), Pembrolizumab (3/10) and Serplulimab used for immune rechallenge (1/10). Follow-up was conducted every 6 weeks ± 3 days, including imaging and hematological assessments. Treatment-related adverse events (AEs) were documented anytime.

RESULTS:

All participants demonstrated stable tolerability and safety in this trial. Immediate post-FUAS ablation rates ranged from 73% to 80%. The median follow-up time is 84 days (IQR, 42-127 days). From baseline to week 18, continuous shrinkage of both hepatic metastatic and target lesions was observed. The DCR of the tumor has reached 80% since the 2nd follow-up (12 weeks), and it remains at 50% until the 4th follow-up (24 weeks).

CONCLUSION:

FUAS sequential with ICIs suggests preliminary safety, activity and feasibility in treating driver-gene wild-type NSCLC patients with liver metastases, further validation is needed.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Mapping research trends in esophageal cancer immunotherapy: A decade of thematic evolution and emerging priorities

Review

Author: Zang, Qiwei ; Jia, Huijun ; Wei, Hongyu ; Gong, Yifan ; Zhao, Chengguang

Immunotherapy has become a pivotal therapy for various cancers, including esophageal cancer, showing promising potential in improving survival rates and enabling personalized care. However, significant challenges occur in identifying predictive biomarkers, refining combination therapies, and managing immunotherapy-related adverse effects. This bibliometric study analyzed publications related to the use of immunotherapy in esophageal cancer management over a 10-y period (January 1, 2015, to October 14, 2024), retrieved from the Web of Science Core Collection. Keyword co-occurrence and co-citation analyses were performed to identify key contributors, central themes, and influential publications. A total of 545 publications on esophageal cancer immunotherapy were included in the analysis. A sharp increase in publication volume was observed beginning in 2019, with a peak between 2021 and 2023. China emerged as the leading contributor, accounting for 67.7% of the total output, while Zhengzhou University produced the highest number of publications among all institutions. Prominent individual contributors included Ken Kato and Shen Lin. Research hotspots centered on PD-1/PD-L1 inhibitors, combination therapies, and tumor microenvironment modulation. Notably, a clear temporal evolution in research focus was observed, with early studies emphasizing specific immune checkpoint targets and agents (e.g., PD-1, Pembrolizumab, and CTLA-4), followed by a shift toward mechanistic investigations involving the tumor microenvironment, treatment resistance, and prognosis. This study provides a comprehensive view of immunotherapy in the management of esophageal cancer, offering direction for future research and valuable insights for clinical innovation.

7,104

News (Medical) associated with Pembrolizumab

22 hours ago

·www.prnewswire.com

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Paxalisib Into a Phase 2 Clinical Study to Evaluate Paxalisib in Immunotherapy-Resistant MSS/pMMR Colorectal Cancer Sept. 1, 2026 -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new preclinical and translational data showing that its lead asset, paxalisib, reduced tumor burden, the total amount of cancer in the body, by 52% (p=0.035) in microsatellite stable (MSS) / proficient mismatch repair (pMMR) colorectal cancer. In a separate study, adding paxalisib to an existing immunotherapy drug reduced tumor volume by an additional 50%, compared with the immunotherapy alone (p=0.022). Across both studies, treatment was well tolerated, with no evidence of treatment-related toxicity. Kazia is also advancing a next-generation translational biomarker program designed to characterize the molecular, immune and epigenetic signatures associated with paxalisib response. The program is intended to identify patients most likely to benefit, provide early measures of biological response, and support biomarker-driven clinical development of paxalisib in pMMR colorectal cancer. These emerging biomarker insights, together with the compelling preclinical findings and a differentiated mechanism of action, have been incorporated into a new patent filing covering aspects of paxalisib's potential use in colorectal cancer, further strengthening the intellectual property foundation for the program as it advances toward clinical development. "Colorectal cancer is one of the leading causes of cancer-related death, and its rising incidence among younger adults underscores the urgent need for new treatment approaches. Using a novel preclinical pMMR model, patient-derived tissue biopsies and single-cell spatial epigenetic profiling, we uncovered a potentially novel mechanism through which paxalisib reprograms the tumor microenvironment to enhance cancer immune visibility, identifying cancer-specific molecular and immune signatures that may explain this shift from immunotherapy-resistant to responsive. Paxalisib showed meaningful anti-tumor activity on its own, and in combination with immunotherapy produced substantially greater tumor reduction in a setting where checkpoint inhibitors have historically provided little benefit. These findings support advancing paxalisib into a Phase 2 study in this patient population, part of our broader strategy to reprogram tumor and immune biology and overcome resistance," said Dr. Sudha Rao, Chief Scientific Officer, Kazia Therapeutics. Patients with MSS/pMMR colorectal cancer account for approximately 85–90% of metastatic colorectal cancer cases. Unlike the smaller subset of colorectal cancers with microsatellite instability (MSI-H), which has shown meaningful response to immune checkpoint inhibitors, published clinical data show that checkpoint inhibitor monotherapy has provided little to no clinical benefit in patients with MSS/pMMR metastatic colorectal cancer. Paxalisib's approach in this setting represents a potential first-in-class strategy, as, to the Company's knowledge, no other PI3K/mTOR inhibitor has previously demonstrated meaningful activity in pMMR colorectal cancer. The Company plans to launch a five-arm Phase 2 clinical trial evaluating paxalisib as a monotherapy in combination with pembrolizumab (Keytruda®) versus standard of care in pre-treated MSS/pMMR metastatic colorectal cancer. Patients will be randomized to one of five arms: paxalisib at 15mg; paxalisib at 15mg plus pembrolizumab, with or without biologic; paxalisib at 30mg; paxalisib at 30mg plus pembrolizumab, with or without biologic; or a standard-of-care comparator arm. The primary endpoint is safety and tolerability, with progression-free survival, overall response rate and overall survival as secondary endpoints. Enrollment is expected to begin in the first quarter of 2027, with full enrollment of all five arms anticipated by the end of 2027. Kazia Therapeutics (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. The Company's lead asset, paxalisib, is an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of over 15 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM AGILE) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. Additionally, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid/rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially first-in-class SETDB1 inhibitor program intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Both programs are currently in preclinical development. The content above comes from the network. if any infringement, please contact us to modify.

ImmunotherapyOrphan DrugFast TrackClinical Result

04 Sep 2026

·www.fiercepharma.com

Fierce Pharma Asia—Roche, GSK, Novartis billion-dollar deals; More MFN sign-ups; Akeso’s OS win

GSK, Roche and Novartis continued Big Pharma's dealmaking spree with Asian companies. Three mid-sized Asian biopharmas reached “most favored nation” deals with the White House. Akeso and Summit Therapeutics' ivonescimab delivered a head-to-head overall survival win against Keytruda. And more. 1. GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset In a deal potentially worth nearly $1.3 billion, GSK is paying Hutchmed $110 million up front to license an antibody-targeted therapy conjugate. The preclinical candidate, coded HMPL-A830, attaches a KRAS inhibitor payload to an anti-EGFR antibody. Clinical development will initially focus on colorectal, pancreatic and lung cancers, with a phase 1 expected to start this year. 2. Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody Roche will gain exclusive global rights to a preclinical trispecific antibody targeting CD79a, CD19 and CD3 from Simcere Zaiming. The deal, up to $1.53 billion, features a $75 million upfront payment. The drug’s mechanism holds potential across B-cell-mediated diseases, including in patients pretreated with CD20- or CD19-directed therapies, according to Simcere. 3. Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact Roche’s Genentech has signed a platform deal to utilize DualityBio’s Dupac antibody-drug conjugate platform. The platform has produced multiple payloads, which are designed to retain efficacy in tumors that progress on topoisomerase-based ADCs. The deal includes a $45 million upfront payment and could be worth more than $1 billion in milestones payments. 4. White House unveils next round of MFN pricing deals with 9 midsized drugmakers Astellas, Kyowa Kirin and Sun Pharma are among nine midsized biopharmas to have signed “most favored nation” drug pricing deals with the Trump administration this week. Besides lowering prices for Medicaid, Astellas will donate 25 kg of tacrolimus active pharmaceutical ingredient to the U.S. strategic reserve. Kyowa highlighted that its agreement includes the deferral of Section 232 tariffs. 5. Akeso, Summit’s ivonescimab extends lives in Keytruda head-to-head trial. What now? The Chinese Harmoni-2 trial, which first sparked hopes that Akeso’s ivonescimab—and the PD-1xVEGF class by extension—could replace Keytruda, has met its overall survival endpoint in first-line PD-L1-positive non-small cell lung cancer. However, with attention circling Summit Therapeutics’ global Harmoni-3 trial, reception to the new topline readout was tepid. 6. Novartis inks $3.2B subcutaneous drug delivery deal with Alteogen Novartis has struck a potential $3.2 billion option and license deal to develop subcutaneous products utilizing Alteogen’s ALT-B4, the same recombinant human hyaluronidase that Merck & Co. uses for its subcutaneous version of Keytruda. AstraZeneca, Biogen and GSK are also among the South Korean company’s customers. 7. Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera Takeda won FDA approval for Mimrylo, or rusfertide, for the rare blood cancer polycythemia vera. It’s the first drug for PV that mimics hepcidin, a hormone that regulates iron in the body, to control overproduction of red blood cells, a hallmark of the disorder. Mimrylo is among three launches that Takeda’s new CEO, Julie Kim, is counting on to drive future growth. 8. Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical data 9. FDA leaders telegraph tightened foreign clinical data oversight (FDA Voices) 10. Patient died in Immunofoco's China IIT trial for CLDN18.2 CAR-T (The Beijing News, Chinese) 11. AZ, Hutchmed combo hits ph.3 goal in first-line lung cancer subtype (release) 12. Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor 13. FDA dings Alar over ‘extremely concerning’ ketamine claims

License out/inDrug ApprovalADC

04 Sep 2026

·allsci.com

Cipla joins Keytruda biosimilar race with Qilu deal

India-based Cipla Limited (BSE: 500087; NSE: CIPLA) has secured exclusive US commercialization rights for QL2107, a biosimilar to pembrolizumab (Keytruda), through an exclusive licensing and supply agreement with China-based Qilu Pharmaceutical. Financial terms were not disclosed. Under the agreement, Qilu retains full responsibility for development, regulatory registration, and supply of QL2107, while Cipla's US subsidiary will handle commercialization exclusively in the United States. QL2107 is a monoclonal antibody biosimilar targeting PD-1, the immune checkpoint receptor targeted by Merck's Keytruda. The asset is currently in Phase III development, with a trial in metastatic non-squamous non-small cell lung cancer initiated in January 2025. No clinical data have been disclosed. The pembrolizumab biosimilar space is among the most competitive in the industry, with at least a dozen programs in active development globally. Germany-based Formycon's FYB206 is among the most advanced candidates, having demonstrated pharmacokinetic equivalence to Keytruda in a pivotal study; Formycon has said a Phase III efficacy study is not required following regulatory feedback. The company partnered with Zydus for US and Canadian commercialization in December 2025. Samsung Bioepis also has an active biosimilar pembrolizumab program with preliminary Phase I data reported in May 2026. QL2107 is therefore entering a crowded development race ahead of the expected loss of key US exclusivity for Keytruda toward the end of the decade, potentially in 2028, although the timing of individual biosimilar launches will depend on regulatory progress and the resolution of relevant patent rights. For Cipla, the deal represents its first disclosed US oncology biosimilar licensing partnership and extends a pattern of in-licensing assets for US commercialization via InvaGen Pharmaceuticals, the subsidiary acquired for USD 550 million in 2016. Cipla's recent US activity has been concentrated in respiratory generics, including FDA approval for a generic of Advair Diskus in July 2026 and approval for a generic of Ventolin HFA in April 2026. The Qilu deal, alongside a cell therapy joint venture announced in January 2024 and a separate exclusive licensing agreement with Sino Biopharmaceutical's SBP Group for TQB2102 announced just days earlier, indicates Cipla is actively diversifying its portfolio into biologics and oncology. For Qilu, the agreement follows a broader strategy of partnering with established commercial operators rather than building proprietary US sales infrastructure. The company said it has US FDA Abbreviated New Drug Application approvals and biosimilars in its pipeline. Cipla's existing generics distribution network provides a commercial foundation suited to a multi-competitor biosimilar market, where payer contracting and pricing execution matter as much as regulatory timing. The next meaningful milestone for the program is completion of Phase III enrollment and a subsequent data readout, which would support Qilu's US biologics license application filing. Spot something wrong? Report an issue with this article

License out/inPhase 3Phase 1ImmunotherapyDrug Approval

100 Deals associated with Pembrolizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10574	Pembrolizumab	L01XC18	DB09037

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Carcinoma of urinary bladder, invasive	European Union	Merck Sharp & Dohme BV	01 Jul 2026
Carcinoma of urinary bladder, invasive	Iceland	Merck Sharp & Dohme BV	01 Jul 2026
Carcinoma of urinary bladder, invasive	Liechtenstein	Merck Sharp & Dohme BV	01 Jul 2026
Carcinoma of urinary bladder, invasive	Norway	Merck Sharp & Dohme BV	01 Jul 2026
Platinum-Resistant Fallopian Tube Carcinoma	China	Merck Sharp & Dohme LLC	23 Jun 2026
Platinum-Resistant Primary Peritoneal Carcinoma	European Union	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Iceland	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Liechtenstein	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Norway	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	European Union	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Iceland	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Liechtenstein	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Norway	Merck & Co., Inc.	02 Apr 2026
Mismatch repair-deficient Colonic Cancer	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Mismatch repair-deficient Colonic Cancer	United States	Merck Sharp & Dohme LLC	10 Feb 2026
Neoplasms	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Neoplasms	United States	Merck Sharp & Dohme LLC	10 Feb 2026
Ovarian Cancer	United States	Merck Sharp & Dohme LLC	10 Feb 2026
Ovarian Cancer	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Muscle Invasive Bladder Carcinoma	United States	Merck Sharp & Dohme Corp.	21 Nov 2025

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Platinum-Resistant Ovarian Carcinoma	NDA/BLA	United States	Merck & Co., Inc.	20 Oct 2025
Small intestine carcinoma	NDA/BLA	European Union	Merck Sharp & Dohme Corp.	25 Mar 2022
Non-small cell lung cancer stage I	Phase 3	United States	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Australia	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Canada	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	France	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Germany	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Greece	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Hungary	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Israel	Merck Sharp & Dohme LLC	04 May 2026

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02617849 (Pubmed \| Oncoimmunology)	Phase 2	Melanoma	30	Pembrolizumab and Carboplatin/ Paclitaxel	fifhzdpskk(dzuflymube) = xfiikevflf quecmjpeyf (mryjityljg ) View more	Negative	31 Dec 2026
KEYNOTE-024 (WCLC2026)	Not Applicable	Non-Small Cell Lung Cancer PD-L1	369	Pembrolizumab-based treatment (Completion group)	rducdrqmhf(septbekmoj) = raydqqgveu fcesuzqyvu (rmrmhoulza ) View more	Positive	12 Sep 2026
				Pembrolizumab-based treatment (Discontinuation group)	rducdrqmhf(septbekmoj) = nuazsdfwzj fcesuzqyvu (rmrmhoulza ) View more
WCLC2026	Phase 3	metastatic non-small cell lung cancer First line	321	Pembrolizumab with chemotherapy	lzgzbghokt(nitwbrixmd): HR = 0.8 (95.0% CI, 0.66 - 0.96)	Positive	12 Sep 2026
				Ipilimumab-nivolumab plus chemotherapy
WCLC2026	Not Applicable	Non-Small Cell Lung Cancer Neoadjuvant	110	Neoadjuvant regimens included tislelizumab/pembrolizumab/mixed	onruvezbgq(ehobjiggec) = eczmwvabuo jhqmqptvgj (idvaoqgcxv ) View more	Positive	12 Sep 2026
NCT04907851 (WCLC2026)	Phase 1/2	Non-Small Cell Lung Cancer	32	Tulmimetostat 200 mg	aioksgxvyb(veynmxdkhy) = 300 mg nnbtzlskgf (johevztiyk )	Positive	12 Sep 2026
				Tulmimetostat 300 mg
WCLC2026	Not Applicable	Non-Small Cell Lung Cancer Neoadjuvant PD-L1 positive \| KRAS inhibitors	120	chemotherapy with nivolumab, durvalumab or pembrolizumab	xfksxacmua(ynzuhfmhbd) = rdbvhunrko pnpprqlepa (nztlauhwog ) View more	Positive	12 Sep 2026
WCLC2026	Not Applicable	Squamous non-small cell lung cancer First line	82	carboplatin+ paclitaxel+ pembrolizumab	ssmyhugmmb(ckelwxvurk) = xbqjbgwoww vqxdkhhynu (ftwoqrpcwd, 11.4 - 23.0) View more	Positive	12 Sep 2026
				pembrolizumab	ssmyhugmmb(ckelwxvurk) = tnkzqccqfg vqxdkhhynu (ftwoqrpcwd, 14.3 - 23.2) View more
WCLC2026	Not Applicable	RIT1-A77G \| ARID1A \| RIT1-M90I ... View more	3	pembrolizumab	lhszrudizt(rjbtbuovdo) = xqdkyizzrt vmlvoicoua (densuhnrqc )	Negative	12 Sep 2026
				Lazertinib/placebo and osimertinib/placebo (RIT1 amplified LUAD with bone metastasis)	lhszrudizt(rjbtbuovdo) = juuqbxgldg vmlvoicoua (densuhnrqc )
WCLC2026	Not Applicable	Non-Small Cell Lung Cancer Neoadjuvant	46	Nivolumab	wygxldcbzp(cektwmwnol) = fbfqtavbhg kwqkmszjym (wznpmtnagt ) View more	Similar	12 Sep 2026
				Pembrolizumab	wygxldcbzp(cektwmwnol) = kgpwglqrjx kwqkmszjym (wznpmtnagt ) View more
WCLC2026	Not Applicable	metastatic non-small cell lung cancer First line	157	pembrolizumab plus platinum‐based chemotherapy (Early ToDA)	ewnykvvuku(injcvescmp) = prgnsfiadu pcoamjtdvo (rwijscexpk ) View more	Positive	12 Sep 2026
				pembrolizumab plus platinum‐based chemotherapy (Late ToDA)	ewnykvvuku(injcvescmp) = fcpvwerium pcoamjtdvo (rwijscexpk ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data